GeneHealth - Your precision medicine

Pleural Mesothelioma Malignant

Disease Details

Family Health Simplified

Buy Membership

Description: Pleural malignant mesothelioma is an aggressive cancer that develops in the lining of the lungs, primarily caused by asbestos exposure.
Type: Pleural malignant mesothelioma is a type of cancer that affects the pleura, which is the thin layer of tissue surrounding the lungs. It is generally not inherited in a clear Mendelian pattern but may have an association with genetic mutations, environmental factors, notably asbestos exposure, and rarely, family history. Certain genetic predispositions, such as mutations in the BAP1 gene, can increase susceptibility.
Signs And Symptoms: Pleural mesothelioma malignant is a rare form of cancer that affects the lining of the lungs (pleura).

### Signs and Symptoms:
1. **Persistent Chest Pain**: Often located under the rib cage.
2. **Shortness of Breath**: Caused by pleural effusion (fluid buildup) or the tumor pressing on the lung.
3. **Chronic Cough**: Persistent and may be accompanied by wheezing.
4. **Unintended Weight Loss**: Often sudden and unexplained.
5. **Fatigue**: General feeling of tiredness or weakness.
6. **Night Sweats**: Excessive sweating during sleep.
7. **Difficulty Swallowing**: Known as dysphagia.
8. **Swelling of the Face and Arms**: Due to pressure on veins transporting blood.

### Diagnostics:
- Imaging studies such as chest X-rays or CT scans.
- Biopsies to confirm the presence of cancerous cells.
- Blood tests to look for markers associated with mesothelioma.

Early detection and treatment are crucial for managing the progression of the disease. If experiencing any of these symptoms, it is important to consult a healthcare professional.
Prognosis: The prognosis for malignant pleural mesothelioma is generally poor. The average survival time after diagnosis ranges from 12 to 21 months, depending on several factors such as the stage of the disease, the patient’s overall health, age, and response to treatment. Advanced stages typically have a worse prognosis, while early detection and aggressive treatment can sometimes improve outcomes.
Onset: The onset of malignant pleural mesothelioma typically occurs 20-50 years after exposure to asbestos, which is the primary risk factor for the disease. Symptoms usually develop gradually and may include chest pain, shortness of breath, and pleural effusion, among others.
Prevalence: The prevalence of malignant pleural mesothelioma is relatively low, as it is a rare cancer. It is estimated to affect approximately 3,000 new individuals in the United States each year. The disease primarily affects older adults, especially those with a history of asbestos exposure.
Epidemiology: Pleural malignant mesothelioma is a rare and aggressive cancer primarily affecting the lining of the lungs (pleura). Its epidemiology includes the following key points:

1. **Incidence and Prevalence**:
- The incidence rate is approximately 1-2 cases per 100,000 people per year in most industrialized countries.
- Higher incidence rates are reported in areas with a history of heavy asbestos use.

2. **Geographic Distribution**:
- Higher prevalence in regions with extensive asbestos industries, such as parts of Australia, the United Kingdom, and Turkey.

3. **Age and Gender**:
- Most common in individuals aged 60-80 years.
- Males are more frequently affected, with a male-to-female ratio of approximately 3:1, likely due to occupational asbestos exposure.

4. **Risk Factors**:
- Asbestos exposure is the predominant risk factor, accounting for over 80% of cases.
- Other factors can include exposure to certain chemicals and radiation, and genetic susceptibility.

5. **Latency Period**:
- The latency period between asbestos exposure and development of the disease can range from 20 to 50 years or more.

6. **Mortality**:
- The prognosis is generally poor, with a median survival time of about 12 months from diagnosis due to the disease's aggressive nature and late presentation.

Understanding these epidemiological factors is crucial for the prevention and management of pleural malignant mesothelioma.
Intractability: Pleural malignant mesothelioma is often considered intractable due to its aggressive nature and late-stage diagnosis. It is challenging to treat effectively. Traditional treatments like surgery, chemotherapy, and radiation therapy generally aim to control symptoms and may extend survival but are rarely curative. Emerging therapies and clinical trials are ongoing to find more effective treatments.
Disease Severity: Pleural malignant mesothelioma is a severe and aggressive form of cancer originating in the pleural lining of the lungs. The prognosis is generally poor, with advanced stages significantly impacting a patient's quality of life and survival rate. Early diagnosis can slightly improve outcomes, but the disease is notoriously difficult to treat effectively.
Healthcare Professionals: Disease Ontology ID - DOID:7474
Pathophysiology: Pleural malignant mesothelioma is a rare and aggressive cancer that develops in the pleura, the thin membrane surrounding the lungs. It is primarily associated with asbestos exposure. Inhaled asbestos fibers become lodged in the lung tissue and pleura, causing chronic inflammation and genetic damage over time. This damage leads to cellular mutations and uncontrolled cell growth, forming malignant tumors in the pleural lining. The cancer can invade local structures like the lung and chest wall and may metastasize to distant organs. The pathophysiology involves complex molecular changes, including alterations in tumor suppressor genes like BAP1, NF2, and CDKN2A, promoting malignancy.
Carrier Status: Pleural malignant mesothelioma is a type of cancer that affects the lining of the lungs, known as the pleura. It is predominantly caused by exposure to asbestos fibers. It is not typically associated with a hereditary carrier status, meaning it is not passed down from parents to children through genes. Instead, the primary risk factor is environmental exposure to asbestos.
Mechanism: Pleural malignant mesothelioma is a rare and aggressive cancer primarily caused by asbestos exposure. It develops in the pleura, the thin membrane surrounding the lungs.

### Mechanism:
The inhalation of asbestos fibers leads to their accumulation in the pleura. These fibers cause direct damage to mesothelial cells and induce chronic inflammation. Over time, the persistent irritation and inflammatory response result in genetic and cellular damage, potentially leading to malignancy.

### Molecular Mechanisms:
1. **Genetic Mutations**:
- **BAP1**: Mutations or deletions in the BRCA1-associated protein 1 (BAP1) gene are common and lead to loss of tumor suppressor function.
- **NF2**: Mutations in the neurofibromin 2 (NF2) gene lead to merlin protein inactivation, affecting cell signal transduction and proliferation.
- **TP53 and CDKN2A**: These genes, which regulate cell cycle and apoptosis, are often mutated or deleted in mesothelioma cells, facilitating unchecked cell growth and resistance to cell death.

2. **Epigenetic Changes**:
- Asbestos exposure induces changes in DNA methylation and histone modification. These epigenetic alterations can inactivate tumor suppressor genes or activate oncogenes.

3. **Inflammatory Pathways**:
- Chronic inflammation caused by asbestos fibers activates nuclear factor kappa B (NF-κB) and other inflammatory pathways, promoting a pro-tumorigenic environment through the secretion of cytokines and growth factors.

4. **Oxidative Stress**:
- Asbestos fibers generate reactive oxygen species (ROS), leading to oxidative DNA damage. This damage contributes to mutagenesis and carcinogenesis.

Understanding these mechanisms is crucial for developing targeted therapies for pleural malignant mesothelioma.
Treatment: Treatment for malignant pleural mesothelioma typically includes a combination of surgery, chemotherapy, and radiation therapy. Surgery aims to remove as much of the cancer as possible, while chemotherapy and radiation therapy are used to kill cancer cells and shrink tumors. In some cases, advanced treatments such as immunotherapy and targeted therapy may also be utilized. Clinical trials may offer additional treatment options, and palliative care is often recommended to manage symptoms and improve quality of life.
Compassionate Use Treatment: Compassionate use treatment and off-label or experimental treatments for malignant pleural mesothelioma (MPM) might include:

1. **Immunotherapy**: Drugs like pembrolizumab and nivolumab, which are generally approved for other cancers, may be considered for MPM on a compassionate use basis.

2. **Gene therapy**: Experimental treatments targeting genetic alterations in mesothelioma cells, often available through clinical trials.

3. **Targeted therapy**: Drugs that target specific molecular pathways, like bevacizumab, which targets the VEGF pathway and is sometimes used off-label.

4. **Tumor Treating Fields (TTF)**: A non-invasive treatment using electric fields to disrupt cancer cell division, available experimentally.

5. **Novel Chemotherapy Agents**: New drugs or combinations of existing drugs that are in clinical trials might be available for compassionate use.

6. **Hyperthermic Intrathoracic Chemotherapy (HITOC)**: A localized, high-temperature chemotherapy treatment used experimentally post-surgery.

Consultation with a specialist and consideration of clinical trials or expanded access programs are often necessary for accessing these treatments.
Lifestyle Recommendations: For malignant pleural mesothelioma, the following lifestyle recommendations can help manage symptoms and improve quality of life:

1. **Smoking Cessation**: If you smoke, quitting can improve lung function and overall health.
2. **Healthy Diet**: Eating a balanced diet rich in fruits, vegetables, and lean proteins can support overall well-being and maintain energy levels.
3. **Regular Exercise**: Gentle physical activities like walking or swimming can help improve stamina and maintain strength. Always consult your doctor before starting any exercise regimen.
4. **Stress Management**: Techniques such as meditation, yoga, or counseling can help manage stress and anxiety.
5. **Adequate Rest**: Ensure you get enough sleep each night to help your body recover and repair.
6. **Avoiding Asbestos**: If you're still in environments where asbestos exposure is a risk, take steps to avoid it completely.
7. **Hydration**: Drink plenty of fluids to stay hydrated, which can help your body function more effectively.
8. **Breathing Exercises**: Practices to enhance lung capacity and ease breathing can be beneficial.
9. **Regular Medical Checkups**: Keep up with your medical appointments to monitor the disease and adjust treatments as needed.

Consulting healthcare professionals for personalized advice and adhering to prescribed treatments is essential in managing malignant pleural mesothelioma effectively.
Medication: For pleural malignant mesothelioma, the medication treatment options typically include chemotherapy drugs such as pemetrexed (Alimta) combined with cisplatin or carboplatin. Additional treatment options can include targeted therapy and immunotherapy drugs like bevacizumab (Avastin) and pembrolizumab (Keytruda). Always consult a healthcare professional for the most appropriate treatment plan.
Repurposable Drugs: Repurposable drugs are medications originally developed for other conditions that are being studied for their potential to treat pleural malignant mesothelioma. Some examples of such drugs include:

1. **Celecoxib**: Initially used as an anti-inflammatory drug, it has shown promise in inducing apoptosis in mesothelioma cells.
2. **Tamoxifen**: Commonly used in breast cancer treatment, this drug has been explored for its potential to inhibit mesothelioma cell growth.
3. **Vorinostat**: A histone deacetylase inhibitor (HDAC inhibitor) used in some forms of cancer therapy, it has shown potential in treating mesothelioma.
4. **Statins**: Medications like simvastatin and atorvastatin, used to lower cholesterol, have demonstrated anti-proliferative effects in mesothelioma cells.
5. **Thalidomide**: Known for its immunomodulatory effects, it has been investigated for its ability to inhibit mesothelioma tumor growth.

These drugs are undergoing various stages of clinical evaluation to confirm their efficacy and safety in treating pleural malignant mesothelioma.
Metabolites: Pleural mesothelioma malignant, a form of cancer affecting the pleura, can involve various metabolic pathways. In terms of metabolites, researchers are studying specific biomarkers and metabolic changes to understand the disease better. These may include elevated levels of certain amino acids, lipids, and other small molecules that contribute to or result from the cancerous processes. However, identifying particular metabolites for diagnostic or therapeutic purposes is still an area of ongoing research.
Nutraceuticals: Research on nutraceuticals for malignant pleural mesothelioma is ongoing, with some studies suggesting potential benefits. However, definitive evidence supporting their efficacy is limited. Common nutraceuticals of interest include curcumin, resveratrol, and certain vitamins and minerals, but they should not replace conventional treatment. Always consult with a healthcare provider for personalized advice. Nanotechnology, on the other hand, is an emerging field in the treatment of malignant pleural mesothelioma. Nanoparticles can be engineered to target cancer cells specifically, potentially improving the effectiveness of chemotherapy and reducing side effects. Research in this area is promising but still in developmental stages.
Peptides: Peptides related to malignant pleural mesothelioma can play roles in diagnosis, treatment, and research. They can be used as biomarkers for early detection, or as therapeutic agents to target cancer cells specifically. Research in nanotechnology is exploring the use of nanoparticles for targeted drug delivery to improve the effectiveness and reduce the side effects of treatments for malignant pleural mesothelioma. These approaches are still largely experimental but represent promising areas for future advancements in the management of this aggressive cancer.